Previous 10 | Next 10 |
The TissueCypher Barrett’s Esophagus test can identify patients at a higher or lower risk of developing esophageal cancer than indicated by pathologic diagnoses and clinical risk factors to guide escalated or de-escalated patient management Data to be highlighted at the 19t...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share a poster detailing new data regarding the Company’s IDgenetix® test at the upcoming Psych Congress 2023 conference, being held in Nashville, Tennessee, Sept...
In the study, management decisions were simulated to determine the most likely care plan with or without use of the TissueCypher test for guidance Study data shows TissueCypher test results significantly improved the likelihood of appropriate management and the consistency of management d...
2023-08-03 11:17:10 ET Shares of Castle Biosciences (NASDAQ: CSTL) were jumping 13.3% higher at 11:01 a.m. ET on Thursday. The nice gain came after the genetic testing company announced its second-quarter results following the market close on Wednesday. Castle reported Q2 revenu...
2023-08-02 22:37:03 ET Castle Biosciences, Inc. (CSTL) Q2 2023 Earnings Conference Call August 02, 2023, 04:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations & Corporate Affairs Derek Maetzold - Founder, President & Chief Exec...
2023-08-02 16:45:40 ET Castle Biosciences press release ( NASDAQ: CSTL ): Q2 GAAP EPS of -$0.70 beats by $0.22 . Revenue of $50.1M (+44.0% Y/Y) beats by $5.86M . Shares +4.23% . Castle Biosciences is increasing its guidance for anticipated total revenue...
Q2 2023 revenue increased 44% over Q2 2022 to $50 million Q2 2023 total test reports increased 52% over Q2 2022 Raising full year 2023 revenue guidance to at least $180 million from $170-180 million Conference call and webcast today at 4:30 p.m. ET Castle Bioscie...
2023-08-01 17:35:59 ET Castle Biosciences ( NASDAQ: CSTL ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, after market close. The consensus EPS Estimate is -$0.91 (-1416.7% Y/Y) and the consensus Revenue Estimate is $44.24M (+27.1% Y/Y). Over th...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Canaccord Genuity 43 rd Annual Growth Conference ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2023, after the close of market on Wednesday, Aug. 2, 2023. Com...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NYSE Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...